A best evidence topic in cardiac surgery was written according to a structured protocol. The question addressed was: Is perioperative corticosteroid administration associated with a reduced incidence of postoperative atrial fibrillation (POAF) in adult cardiac surgery? A total of 70 papers were identified using the search as described below. Of these, eight were identified to provide best evidence to answer the clinical question. These papers consisted of well-designed, double-blinded randomized control trials (RCTs) or meta-analysis of RCTs that presented sufficient data to reach conclusions regarding the issues of interest for this review. Postoperative atrial fibrillation occurrence, outcomes and complications were included in the assessment. The author, date and country of publication, patient group studied, study type, relevant outcomes, results and study weaknesses of the papers are tabulated. Literature search showed that the prophylactic use of hydrocortisone (100 mg/day, 4 days) can reduce the incidence of POAF to 30%, compared with 48% in the control group (P = 0.004). One gram of methylprednisolone before surgery followed by 4 mg of dexamethasone every 6 h for 1 day after surgery was also associated with a significant reduction in POAF (21 vs 51%; P = 0.003). Moreover, a single dose of dexamethasone (0.6 mg/kg) can significantly diminish POAF (18.95 vs 32.3%; P = 0.027). The changes in POAF appeared greatest in patients receiving intermediate doses of corticosteroid (50-210 mg of dexamethasone equivalent), while both lower (up to 8 mg) and higher (236-2850 mg) dosing resulted in blunted effects. Similarly, a moderate dose of hydrocortisone (200-1000 mg/day) is as effective as high (1001-10 000 mg/day) and very high doses (10 000 mg/day). Although the optimal dose, dosing interval and duration of therapy are unclear, meta-analysis suggests that a single dose can be as effective as multiple doses. No statistically significant complications associated with the use of corticosteroids were reported in any of the studies. We conclude that a single prophylactic moderate dose of corticosteroid (50-210 mg of dexamethasone equivalent or 200-1000 mg/day hydrocortisone) can significantly reduce the risk of POAF with no significant increase in morbidity or mortality.
INTRODUCTION
A best evidence topic was constructed according to a structured protocol. This is fully described in the ICVTS [1] . 
THREE-PART QUESTION

CLINICAL SCENARIO
A 72-year old male patient with severe triple-vessel coronary artery disease is referred for coronary artery bypass surgery. He has no significant past medical history. He is scheduled for elective coronary artery bypass graft, and the question is whether perioperative prophylaxis with corticosteroids for AF is appropriate. 
SEARCH STRATEGY
Medline
Outcomes and complications:
There were no statistically significant differences between the groups with respect to postoperative complications (P > 0.99)
All patients were administered β-blockers according to the heart rate The group adjusted for potential imbalanced confounders and found that the association between randomization to hydrocortisone and POAF was unchanged
The study was underpowered to assess the safety of corticosteroid therapy The dose response of corticosteroid was assessed by two methods:
Continued
(i) Trials were stratified into three broad dose strata (low, medium and high)
(ii) The dose of corticosteroid was used as a continuous predictor in meta-regression to assess whether the dose of corticosteroid affected the rate of AF between the studies Corticosteroid prophylaxis is effective in reducing the risk of postoperative AF and this benefit was not significantly different between different doses of corticosteroid Corticosteroid prophylaxis may represent a very cost-effective preventive strategy in adult cardiac surgery
POAF:
Corticosteroid prophylaxis reduced the risk of AF (25.1 vs 35.1%; number needed to treat, 10; relative risk, 0.74; 95% CI 0.63-0.86; P < 0.01)
Outcomes and complications:
Corticoids are associated with a significant reduction in the length of stay in the ICU (weighted mean difference −0.37 days; 95% CI, −0.21 to −0.52; P < 0.01) and hospital (weighted mean difference −0.66 days; 95% CI −0.77 to −1.25; P = 0.03)
Corticosteroid did not increase the risk of all-cause
The group adjusted for publication bias and restricted the analysis to higher quality studies (n = 14) and showed similar results
Restricting the analysis to studies that did not use routine postoperative β-blocker therapy, or recruited only coronary artery bypass graft surgery, did not change the effects of corticosteroid on risk of POAF and all-cause infection. The group adjusted for the different doses of corticosteroid between the studies
RESULTS
Halonen et al. [4] showed in a multicentre randomized control trial (RCT) of 241 patients who received either 100 mg hydrocortisone or matching placebo (one dose in the evening of the operation, then one dose every 8 h during the next 3 days) that the incidence of postoperative atrial fibrillation (POAF) was significantly lower in the hydrocortisone group (30 vs 48%; P = 0.004). In this study, patients receiving hydrocortisone did not have higher rates of wound infections or other major complications. Similarly, Yared et al. [2] randomized 235 patients to receive a single dose of dexamethasone 0.6 mg/kg or placebo at induction, and found that patients receiving dexamethasone had a lower incidence of POAF during the first 3 days postoperatively (18.9 vs 32.3%; P = 0.027). No statistical differences in the intensive care and hospital length of stay or in overall morbidity and mortality were noted.
Prasongsukarn et al. [3] enrolled 88 patients in their RCT (43 patients received 1 g of methylprednisolone before surgery and 4 mg of dexamethasone every 6 h for 1 day after surgery). This study found that POAF occurred in 9 (21%) in the steroid group and 22 (51%) in the placebo group (P = 0.003). Minor postoperative complications occurred in 15 (35%) steroid patients and in 6 (14%) patients receiving placebo (P = 0.01), and no significant differences noted in major complications. It is important to note that in this study after 50% enrolment, the code was broken, and the data showed that the primary outcome was satisfied (AF incidence) so the study was stopped, which can have large implications for the secondary outcomes. The role of steroid prophylaxis in high-risk cardiac patients was addressed by Weis et al. [9] in an RCT of 36 high risk who were randomized to hydrocortisone (loading dose of 100 mg before induction and followed by a continuous infusion of 10 mg/h for the first day reduced to 5 mg/h on the second day and then tapered to 3 × 20 mg on Day 3 and 3 × 10 mg on Day 4) or placebo and showed that patients in the hydrocortisone group had a lower incidence of POAF (26 vs 59%; P = 0.04) and shorter length of stay in the intensive care unit (ICU; 2 [2 of 3] vs 6 [4 of 8] days; P = 0.001).
Ho and Tan [7] analysed 50 RCTs including 3323 patients and demonstrated that corticosteroid prophylaxis reduced the risk of POAF (25.1 vs 35.1%; number needed to treat, 10; relative risk 0.74; 95% confidence interval [95% CI] 0.63-0.86; P < 0.01) and length of stay in the ICU (weighted mean difference −0.37 days; 95% CI −0.21 to −0.52; P < 0.01) and hospital (weighted mean difference −0.66 days; 95% CI −0.77 to −1.25; P = 0.03) compared with placebo. Furthermore, the use of corticosteroid was not associated with an increased risk of all-cause infection (relative risk 0.93; 95% CI 0.61-1.41; P = 0.73). The authors noted that no additional benefits were found beyond a total dose of 1000 mg hydrocortisone. Similar outcomes were demonstrated by Whitlock et al. [8] in a meta-analysis of 44 trials including 3205 patients that showed that steroids can reduce POAF (relative risk 0.71; 95% CI 0.59-0.87; P = 0.001), postoperative bleeding (weighted mean difference −99.6 ml, 95% CI −149.8 to −49.3) and duration of ICU stay (weighted mean difference −0.23 days; 95% CI −0.40 to −0.07).
Marik and Fromm [5] in a meta-analysis of seven studies that included 1046 patients found that the use of corticosteroids was associated with a significant reduction in the risk of POAF (odds ratio 0.42; 95% CI 0.27-0.68; P = 0.0004). The group reported significant heterogeneity between studies in terms of the corticosteroid regimen used with the total cumulative dose varying from 160 to 21 000 mg of hydrocortisone equivalents. When the low-dose (<200 mg/day) and very high-dose (10 000 mg/day) studies were excluded, the treatment effect was highly significant (odds ratio 0.32; 95% CI 0.21-0.50; P < 0.00001) with insignificant heterogeneity. Similar conclusions were reported by Baker et al. [6] in their meta-analysis of nine studies including 990 patients that showed that corticosteroids were associated with a significant reduction in POAF by 45% (odds ratio 0.55; 95% CI 0.39-0.78; P = 0.0009) and reduced hospital length of stay by 1.6 days (weighted mean difference −1.59; 95% CI −2.96 to −0.21). The reduction in POAF appeared greatest in patients receiving intermediate doses of corticosteroid (50-210 mg of dexamethasone equivalent), while both lower (up to 8 mg) and higher (236-2850 mg) dosing resulted in blunted effects.
CLINICAL BOTTOM LINE
We conclude that a moderate prophylactic dose of corticosteroid prophylaxis (50-210 mg of dexamethasone equivalent or 200-1000 mg/day hydrocortisone) can significantly reduce the risk of POAF with no significant increase in morbidity or mortality. Although the optimal dose, dosing interval and duration of therapy are unclear, a single dose given at induction may be adequate.
There is, however, need for more specific research to gain a better understanding of the mechanisms involved in modulating POAF and the ideal steroid prophylaxis protocol.
